We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sixty percent of the public surveyed say they believe a treatment or vaccine for COVID-19 will be developed in just under a year. And once developed, 64 percent said they thought it would be less than a year before the public could begin receiving a COVID-19 treatment or vaccine. Read More
The highly politicized debate over whether hydroxychloroquine is or is not useful to COVID-19 patients appears to be far from over. A coalition of more than 180 doctors and researchers have signed an open letter questioning the findings of a study showing that hydroxychloroquine and chloroquine have no benefit in treating COVID-19 patients. Read More
PureTech Health said it will begin human trials on an experimental treatment for respiratory complications following recovery from COVID-19 infections. Read More
Novartis-subsidiary AveXis has entered into an agreement to manufacture a COVID-19 vaccine being developed by Massachusetts General Hospital and Massachusetts Eye and Ear. Read More
Roche has begun a phase 3 trial of its rheumatoid arthritis treatment Actemra (tocilizumab) with Gilead Sciences’ remdesivir for treatment of patients with severe COVID-19 pneumonia. Read More
Another study — the largest to date — has shown that anti-malaria drugs hydroxychloroquine and chloroquine have no benefit in treating COVID-19, in fact have a negative effect on patient survival and are associated with an increase in ventricular arrhythmias. Read More